Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SynCo Bio Partners (SynCo) and Versartis have extended their strategic partnership following an initiation of Phase 1 clinical trial of VRS-859 in type 2 diabetes mellitus (T2DM) patients with monthly dosing of the drug.
Subscribe to our email newsletter
Versartis said that VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency.
Earlier, SynCo Bio Partners (SynCo) and Versartis entered into a strategic partnership to manufacture Versartis’ product VRS-859.
As per the terms of the extended agreement, SynCo is expected to scale-up a second manufacturing process on behalf of Versartis, this time in preparation for the GMP manufacture of VRS-317.
SynCo is also expected to provide fill and finish services for the manufacture, testing and release of formulated drug product vials.
SynCo said that it has completed process development and optimisation, scale-up and GMP manufacture of VRS-859 for Phase 1 clinical studies earlier this year.
Jeffrey Cleland, CEO of Versartis, said: “We look forward to a successful partnership for our second product, VRS-317.”
Pierre Warffemius, CEO of SynCo Bio Partners, said: “The VRS-859 manufacturing program was completed on time due to the combined expertise and management of the Versartis-SynCo project team. We very much look forward to helping Versartis also meet their corporate objectives for VRS-317.”